Company Interview / Artrya strengthening its global pulse with contract wins

Mathew Regan from Artrya states that the company secures major contracts with Sonic Healthcare and Loomis Imaging in Australia. The Salix platform gains FDA clearance, paving the way for US commercialisation with strategic partners Tanner, Northeast Georgia, and Cone Health Systems.

Mathew mentions that while Australian contracts offer credibility, the US is the key revenue driver. FDA clearance allows noninvasive solutions for coronary analysis, aiming to unlock significant rebate codes by early next year. Additional FDA clearances for plaque and flow products are in progress.

A recent $15 million capital raise boosts Artrya's financial position, enabling further US market penetration. Mathew outlines future aspirations including global expansion with regulatory approvals in New Zealand, UK, Europe, and beyond.